{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"59"}]}],"title":"Participants who reduced/discontinued ITP therapy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"41"}]}],"title":"Participants not reducing/discont. ITP therapy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"134"}],"units":"Participants"}],"description":"Percentage of participants who experienced a reduction in their baseline concomitant ITP medication use","groups":[{"description":"Matching placebo tablets taken once a day","id":"OG000","title":"Placebo"},{"description":"Eltrombopag 50 mg oral tablets taken once a day (QD)","id":"OG001","title":"Eltrombopag 50 mg QD"}],"paramType":"NUMBER","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"From Day 1 through Week 26 on-treatment","title":"Percentage of Participants With a Reduction in Use of Baseline ITP Medication","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}